Otsuka Group News

Keyword search

Search by company	Otsuka Holdings Otsuka Pharmaceutical Otsuka Pharmaceutical Factory Taiho Pharmaceutical Otsuka Warehouse Otsuka Chemical Otsuka Foods Otsuka Medical Devices Other
Search by category^*	Pharmaceuticals Business Nutraceuticals Business Consumer Products Business Others Products R&D Personnel Corporate * Business categories are based on the business segments described in the financial announcements.
Search by release date	-

February 20, 2025
Otsuka Pharmaceutical

Otsuka Sponsor TOKYO MARATHON 2025 Supporting the Conditioning of Runners Worldwide with the Global Brand POCARI SWEAT
February 19, 2025
Otsuka HoldingsOtsuka Pharmaceutical

Otsuka Holdings Receives Award by the Commissioner of the Consumer Affairs Agency at FY2024 Award for Good Practices of Consumer-Oriented Management　- Recognized for Otsuka Pharmaceutical’s Longstanding Efforts to Prevent Heat Disorders-
February 18, 2025
Otsuka Foods

Otsuka Foods to Release Mannan Gohan with Glutinous Barley and Brown Rice Providing Approx. Five Times the Dietary Fiber of White Rice or Half the Recommended Daily Intake In Stores Across Japan on March 3, 2025
February 14, 2025
Otsuka Holdings

Otsuka Holdings Announces Personnel Changes
February 14, 2025
Otsuka Pharmaceutical

Otsuka Pharmaceutical to Offer "Wellness Energy" at the Expo 2025 Osaka, Kansai, Japan Introducing a New Vision for “Shaping the Health of the Future”
February 13, 2025
Otsuka Pharmaceutical

Otsuka Pharmaceutical Finalizes an Agreement with Fukuroi City on the Horizontal Recycling of PET Bottles Partnering with Its Factory to Promote a “Local Production and Local Recycling” Initiative for PET Bottles
February 7, 2025
Otsuka Holdings

Otsuka Group Selected for CDP Climate Change A List for a Third Consecutive Year
February 5, 2025
Otsuka Foods

Otsuka Foods to Release “Bon Curry NEO Ninniku Mashi Mashi: Hot” Enhanced Umami with Double the Garlic, Beef Sauteed in Red Wine, and a Rich Sauce In Stores across Japan from March 17, 2025
January 29, 2025
Taiho Pharmaceutical

Taiho Pharmaceutical, Taiho Oncology, and Cullinan Therapeutics Announce Primary Endpoint Met in Phase 2b Trial of Zipalertinib in Patients with Non-Small Cell Lung Cancer Harboring EGFR Exon 20 Insertion Mutations Who Have Received Prior Therapy
January 23, 2025
Otsuka Pharmaceutical

Otsuka Pharmaceutical Launches the “Conditioning Supporter Training Program” Encouraging the Practice of Self-Conditioning
January 21, 2025
Otsuka Pharmaceutical

Otsuka Pharmaceutical Releases the Total Conditioning Handbook for Well-Being to Support Life Performance
January 14, 2025
Otsuka Pharmaceutical

MIREVO, the first neuropsychological testing program in Japan to support dementia treatment, now available
January 10, 2025
Otsuka Pharmaceutical

Otsuka Announces FDA Plans to Host an Advisory Committee Meeting to Discuss the sNDA for Brexpiprazole in Combination with Sertraline for the Treatment of Adults with Post-Traumatic Stress Disorder (PTSD)
January 6, 2025
Otsuka Pharmaceutical

European Medicines Agency Commences Review of Donidalorsen in Hereditary Angioedema
December 23, 2024
Otsuka Foods

Otsuka Foods to Revise Prices of Some Products New Prices to Take Effect with Deliveries as of March 1, 2025
December 19, 2024
Otsuka Pharmaceutical

Detailed Findings in JAMA Psychiatry Show Otsuka and Lundbeck’s Phase 3 Trial of Brexpiprazole in Combination with Sertraline Significantly Improved Symptoms of Post-Traumatic Stress Disorder (PTSD) in Adults
December 12, 2024
Otsuka Pharmaceutical

Otsuka and Jolly Good initiate the sale of FACEDUO Dementia Care Support VR
December 5, 2024
Otsuka Pharmaceutical

Otsuka Expanding Use of Environmentally Friendly, Reusable Temperature-Controlled Containers
November 27, 2024
Otsuka Pharmaceutical

Otsuka Pharmaceutical Launches POCARI SWEAT Basketball Dream Project to Promote Sports and International Exchanges
November 26, 2024
Otsuka Pharmaceutical

Otsuka Submits New Drug Application in Japan for Bempedoic Acid in the Treatment of Hypercholesterolemia
November 22, 2024
Otsuka Pharmaceutical

Otsuka Obtains Exclusive Global Licensing Rights from Ionis to Ulefnersen, a Potential Treatment for Amyotrophic Lateral Sclerosis Caused by Mutations in the Fused in Sarcoma Gene (FUS-ALS)
November 20, 2024
Otsuka Pharmaceutical

Otsuka launches Lupkynis in Japan
November 19, 2024
Otsuka Pharmaceutical

Otsuka Provides Update on Sibeprenlimab, an Investigational Monoclonal Antibody for the Treatment of IgA Nephropathy in Adults
November 13, 2024
Otsuka Pharmaceutical Factory

Otsuka Pharmaceutical Factory and ICU Medical Announce the Establishment of Joint Venture
November 5, 2024
Taiho Pharmaceutical

Taiho Innovations, LLC. Selected as a Registered Venture Capital in AMED’s Strengthening Program for Pharmaceutical Startup Ecosystem
October 31, 2024
Otsuka HoldingsOtsuka Pharmaceutical

Otsuka Announces Personnel Changes
October 29, 2024
Otsuka HoldingsOtsuka Pharmaceutical Factory

Supply of Renewable Energy to Business Partners -Towards Achieving Carbon Neutrality Throughout Our Supply Chain-
October 22, 2024
Otsuka Pharmaceutical

Otsuka Announces Positive Interim Results from the Phase 3 Trial of Sibeprenlimab for the Treatment of Immunoglobulin A Nephropathy in Adults
September 30, 2024
Otsuka HoldingsOtsuka Pharmaceutical

Otsuka Group Establishes Solar Power Generation Facility in Naka, Tokushima The New Facility Advances the Company’s Carbon Neutrality Initiative
September 30, 2024
Otsuka Pharmaceutical Factory

EN Otsuka Pharmaceutical Co., Ltd. obtains marketing approval of "ENOSOLID Semi Solid for Enteral Use"

Otsuka Group News

First 30 results